- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist, Placebo
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–1
of 1
matching trial from the live ClinicalTrials.gov search.
Filters: Intervention: Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist Clear all